Wisdom : In July of last year we wrote a report on Idenix Pharmaceuticals ( IDIX ) indicating that a small chance of a potential ..... 48% of Idenix, the market was pessimistic on IDIX 's nucleotide development and that Idenix's management
Shares of Idenix Pharmaceuticals ( IDIX ) are up almost 17% premarket on no significant news. Consensus revenue estimates for 2014 and 2015 are $1.5M and $7.7M
In its Q4 13F , activist investor Sarissa Capital discloses it has a 5.05M-share (3.3%) stake in Idenix Pharmaceuticals ( IDIX +1.8% ). Shares initially jumped on the disclosure, but have quickly given back some of their gains
Top gainers, as of 5:15 p.m.: MYGN +14.5% . USNA +14.1% . IDIX +7.3% . SFLY +6.9% . GIMO +6.8% . Top losers, as of 5:15 p.m.: QNST -15.1% . XOOM -12.9% . PACB -9.7% . KEYW -8.4% . HAIN -7.9% . Post your comment!
Top gainers, as of 5:15 p.m.: MYGN +15.5% . USNA +14.0% . OCLR +8.4% . IDIX +7.3% . GIMO +4.9% . Top losers, as of 5:15 p.m.: QNST -15.1% . XOOM -9.4% . HAIN -7.9% . KEYW -6.9% . CHRW -6.5% . Post your comment!
Baupost's latest 13D shows a 39.8%, or 53.3M share stake in Indenix Pharmaceuticals ( IDIX ) vs 35% at last report . Baupost also say's it's engaged management and has been granted observer rights to board meetings. Shares +7.3% AH Post your comment!
Idenix Pharmaceuticals ( IDIX ) has received a net $106.7M by selling 16.42M shares to the The Baupost Group at $6.50 each vs Idenix's close of $6
Five months after upgrading Idenix ( IDIX -7.8% ) to Market Perform, JMP has downgraded the HCV drug developer back to Underperform. Going into today, Idenix had nearly doubled from the time of JMP's upgrade. Post your comment!
(Reuters) - Shares of Idenix Pharmaceuticals Inc rose as much as 16 percent on Wednesday, after the company reported positive mid-stage trial data of its hepatitis C drug, suggesting it was closer...
We are no longer providing equity research on Idenix Pharmaceuticals IDIX . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.